No profile data available.
MannKind Corporation (MNKD) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Danbury, United States, with about 591 full-time employees.
It reported revenue of $285.50 million for fiscal year 2024, up 43.5% from fiscal year 2023, and net income of $27.59 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $82.13 million, up 17.2% from a year before. Its market capitalization was $1.06 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
MannKind reported $285.50 million in revenue for fiscal year 2024, up 43.5% from $198.96 million in fiscal year 2023. In Q3 2025 revenue was $82.13 million.
$1.06 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sana Biotechnology, Inc. (SANA), Oculis Holding AG (OCS), Amphastar Pharmaceuticals, Inc. (AMPH), MoonLake Immunotherapeutics (MLTX).